BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22858904)

  • 1. Tubal ligation frequency in Oklahoma women with cervical cancer.
    Mathews CA; Stoner JA; Wentzensen N; Moxley KM; Tenney ME; Tuller ER; Myers T; Landrum LM; Lanneau G; Zuna RE; Gold MA; Wang SS; Walker JL
    Gynecol Oncol; 2012 Nov; 127(2):278-82. PubMed ID: 22858904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for cervical cancer despite extensive screening.
    Stenkvist B; Söderström J
    J Med Screen; 1996; 3(4):204-7. PubMed ID: 9041486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compliance with Papanicolaou smear screening following tubal ligation in women with cervical cancer.
    Winkler HA; Anderson PS; Fields AL; Runowicz CD; DeVictoria C; Goldberg GL
    J Womens Health; 1999; 8(1):103-7. PubMed ID: 10094087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of endocervical curettage in women with low-grade squamous intraepithelial lesions or atypical squamous cells of unknown significance on Pap smear.
    Miranda AD; Rodríguez R; Novoa DM; Rojas A; Pachón A; DiazGranados CA
    J Low Genit Tract Dis; 2006 Jul; 10(3):146-50. PubMed ID: 16829753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papilloma virus testing knowledge and attitudes among women attending colposcopy clinic with ASCUS/LGSIL pap smears.
    Le T; Hicks W; Menard C; Boyd D; Hewson T; Hopkins L; Kee Fung MF
    J Obstet Gynaecol Can; 2004 Sep; 26(9):788-92. PubMed ID: 15361273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy.
    Cox JT; Schiffman M; Solomon D;
    Am J Obstet Gynecol; 2003 Jun; 188(6):1406-12. PubMed ID: 12824970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimally abnormal Pap testing and cervical histology in HIV-infected women.
    Curry CL; Sage YH; Vragovic O; Stier EA
    J Womens Health (Larchmt); 2012 Jan; 21(1):87-91. PubMed ID: 22011239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of high risk factors associated with cervical intraepithelial neoplasia in married women aged 25 - 54 years in Beijing between 2007 - 2008].
    Li CD; Zhang WY; Wu MH; Zhang SW; Zhou BL; Zhu L; Pan J; Wang JD
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):757-61. PubMed ID: 21176557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX1 methylation as a potential biomarker for cervical cancer screening.
    Kan YY; Liou YL; Wang HJ; Chen CY; Sung LC; Chang CF; Liao CI
    Int J Gynecol Cancer; 2014 Jun; 24(5):928-34. PubMed ID: 24844223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China.
    Pan QJ; Hu SY; Zhang X; Ci PW; Zhang WH; Guo HQ; Cao J; Zhao FH; Lytwyn A; Qiao YL
    Cancer Cytopathol; 2013 Sep; 121(9):473-82. PubMed ID: 23907807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus.
    Massad LS; DʼSouza G; Tian F; Minkoff H; Cohen M; Wright RL; Colie C; Hessol NA
    Obstet Gynecol; 2012 Oct; 120(4):791-7. PubMed ID: 22996096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.